SweetSpot Case Study

Transforming Diabetes Care Through Connected Technology and Clinical Support

Founded in 2020, SweetSpot is a digital health company that partners with endocrinology practices to deliver comprehensive, end-to-end diabetes care management services. The company’s centralized platform integrates continuous glucose monitor (CGM) and insulin pump data with real-time clinical support from certified diabetes educators, helping providers better manage patient outcomes.

In addition to improving care, SweetSpot’s platform automatically captures reimbursable care events—creating new revenue streams for practices while enhancing patient engagement. With an experienced leadership team that includes co-founders Stephen Von Rump (CEO), Dr. Ralph Oiknine (CMO), Abby Cohen (COO), and Dr. Amiad Fredman (CPO), SweetSpot is redefining how diabetes care is delivered and sustained.

SweetSpot Highlights

SweetSpot’s rapid progress since launch reflects both its technological innovation and its strong market adoption:

• Rapid Growth: The company achieved $1.5 million in annual recurring revenue (ARR) as of Q2 2025, maintaining 50%+ quarter-over-quarter growth as demand for connected diabetes care solutions expands.
• Industry Recognition: Named a 2025 “Company to Watch” by the American Diabetes Association, acknowledging its role in advancing digital diabetes care.
• Clinical Validation: A 2024 retrospective trial demonstrated that patients using SweetSpot’s platform experienced a 10%+ improvement in Glucose Time in Range with more frequent clinician touchpoints.
• Leadership Expansion: In 2024, SweetSpot welcomed Dr. Mary Jo Gorman to its Board of Directors, bringing extensive healthcare leadership experience to support the company’s next stage of growth.

Community Support: Winner of an Arch Grant in 2023 and an Arch Grant Growth Grant in 2025, further validating the company’s innovation and local impact.

BioGenerator’s Role in SweetSpot’s Success

SweetSpot was co-founded by BioGenerator and BioGenerator Entrepreneur-in-Residence (EIR) Stephen Von Rump, reflecting our commitment to launching innovative, scalable healthtech companies in St. Louis. BioGenerator became the company’s first professional investor in 2021, providing critical early capital and operational guidance.

The company’s leadership team also includes BioGenerator Venture Fellow Dr. Amiad Fredman, who joined as Chief Product Officer, and BioGenerator EIR David Christenson, who serves on the Board of Directors. Since 2021, BioGenerator has invested $900,000 in SweetSpot, supporting its continued expansion and technological advancement.

Through strategic investment, mentorship, and ecosystem connections, BioGenerator helped transform SweetSpot from a local startup into a fast-growing leader in digital diabetes management.

"We are privileged to be a product of the BioGenerator and BioSTL ecosystem, which has created so many important companies in St. Louis. We thank BioSTL leadership for their support, and the opportunity to achieve the success we are now realizing that would not have otherwise been possible."

Stephen Von Rump, Founder & CEO, SweetSpot Digital Health